Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Juno Therapeutics Inc. (JUNO) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (45)	11/23/2016 3:39:27 PM
From: scaram(o)uche	Read Replies (4) \| Respond to of 84

Well, we got that. Ugh. Ugh, ugh, ugh, ugh. I am, however, surprised at the bitter tone of sector journalists, aimed at Bishop et al. and FDA. Clinical trial participants are heroes, and informed consent of this extreme nature is countered by the chance for a durable, long-term remission. FDA walks that line, and everyone at FDA would love to throw around the c word. A better therapeutic window is needed, that is certain. May need to infuse cells in the presence of a modulator, and slowly release the brakes. Need transformation-specific antigens, and tools to recognize extremely "weak" ones. I'd go on, but my circa-2000 perspective and insights would show. Not certain if blcm ever disclosed the start of this trial..... clinicaltrials.gov